DHDa Wei Huang

Da Wei Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Da Wei Huang has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Figures S1-10 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas

    by Sebastian Scheich, Jiji Chen, Jiamin Liu, Frank Schnütgen, Julius C. Enssle, Michele Ceribelli, Craig J. Thomas, Jaewoo Choi, Vivian Morris, Tony Hsiao, et al.

    Supplemental Figure 1. IRF4-GFP knock-in reporter cell lines. Supplemental Figure 2. IRF4-GFP CRISPR screen in adult T-cell lymphoma and screen controls. Supplemental Figure 3. The OST is essential for DLBCL. Supplemental Figure 4. The role of the OST complex in radiation chimeras. Supplemental Figure 5. The B-cell receptor is glycosylated by the OST complex. Supplemental Figure 6. B-cell receptor deglycosylation leads to higher surface expression. Supplemental Figure 7. B-cell receptor deglycosylation leads to signaling changes in proximal BCR signaling components. Supplemental Figure 8. BCR deglycosylation leads to recruitment of CD22 on the cell surface to the BCR and signaling alterations in GCB DLBCL. Supplemental Figure 9. BCR internalization and My-T-BCR formation in glycosylation deficient cells. Supplemental Figure 10. NGI-1 synergizes with BTK and PI3K inhibitors.

  • Open Access

    Supplementary Tables S1-S12 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas

    by Sebastian Scheich, Jiji Chen, Jiamin Liu, Frank Schnütgen, Julius C. Enssle, Michele Ceribelli, Craig J. Thomas, Jaewoo Choi, Vivian Morris, Tony Hsiao, et al.

    Table S1. Brunello library sgRNA normalized read counts of IRF4 sorted CRISPR screens. Table S2. Segregation score of IRF4 sorted CRISPR screens. Table S3. Glycoproteomics in STT3A or STT3B KO cells. Table S4. Brunello sgRNA Library Normalized Read Counts of CRISPR screens. Table S5. CRISPR screen score of essentiality screens. Table S6. Glycoproteomics after NGI-1 treatment. Table S7.HBL1 and TMD8 Phosphotyrosone Phosphoproteome (pYome). Table S8. TMD8 CD79A-BioID. Table S9. HBL1 CD22 BioID. Table S10. Brunello library sgRNA normalized read counts of NGI-1 drug modified screen (TMD8). Table S11. CRISPR screen score of NGI-1 drug modifier screen. Table S12. TMD8 Drug screen Excess HSA.

  • Open Access

    Supplementary Tables S1-S12 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas

    by Sebastian Scheich, Jiji Chen, Jiamin Liu, Frank Schnutgen, Julius C. Enssle, Michele Ceribelli, Craig J. Thomas, Jaewoo Choi, Vivian Morris, Tony Hsiao, et al.

    Table S1. Brunello library sgRNA normalized read counts of IRF4 sorted CRISPR screens. Table S2. Segregation score of IRF4 sorted CRISPR screens. Table S3. Glycoproteomics in STT3A or STT3B KO cells. Table S4. Brunello sgRNA Library Normalized Read Counts of CRISPR screens. Table S5. CRISPR screen score of essentiality screens. Table S6. Glycoproteomics after NGI-1 treatment. Table S7.HBL1 and TMD8 Phosphotyrosone Phosphoproteome (pYome). Table S8. TMD8 CD79A-BioID. Table S9. HBL1 CD22 BioID. Table S10. Brunello library sgRNA normalized read counts of NGI-1 drug modified screen (TMD8). Table S11. CRISPR screen score of NGI-1 drug modifier screen. Table S12. TMD8 Drug screen Excess HSA.

  • Open Access

    Supplementary Tables S1-S12 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas

    by Sebastian Scheich, Jiji Chen, Jiamin Liu, Frank Schnutgen, Julius C. Enssle, Michele Ceribelli, Craig J. Thomas, Jaewoo Choi, Vivian Morris, Tony Hsiao, et al.

    Table S1. Brunello library sgRNA normalized read counts of IRF4 sorted CRISPR screens. Table S2. Segregation score of IRF4 sorted CRISPR screens. Table S3. Glycoproteomics in STT3A or STT3B KO cells. Table S4. Brunello sgRNA Library Normalized Read Counts of CRISPR screens. Table S5. CRISPR screen score of essentiality screens. Table S6. Glycoproteomics after NGI-1 treatment. Table S7.HBL1 and TMD8 Phosphotyrosone Phosphoproteome (pYome). Table S8. TMD8 CD79A-BioID. Table S9. HBL1 CD22 BioID. Table S10. Brunello library sgRNA normalized read counts of NGI-1 drug modified screen (TMD8). Table S11. CRISPR screen score of NGI-1 drug modifier screen. Table S12. TMD8 Drug screen Excess HSA.

  • Open Access

    Supplementary Figures S1-10 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas

    by Sebastian Scheich, Jiji Chen, Jiamin Liu, Frank Schnutgen, Julius C. Enssle, Michele Ceribelli, Craig J. Thomas, Jaewoo Choi, Vivian Morris, Tony Hsiao, et al.

    Supplemental Figure 1. IRF4-GFP knock-in reporter cell lines. Supplemental Figure 2. IRF4-GFP CRISPR screen in adult T-cell lymphoma and screen controls. Supplemental Figure 3. The OST is essential for DLBCL. Supplemental Figure 4. The role of the OST complex in radiation chimeras. Supplemental Figure 5. The B-cell receptor is glycosylated by the OST complex. Supplemental Figure 6. B-cell receptor deglycosylation leads to higher surface expression. Supplemental Figure 7. B-cell receptor deglycosylation leads to signaling changes in proximal BCR signaling components. Supplemental Figure 8. BCR deglycosylation leads to recruitment of CD22 on the cell surface to the BCR and signaling alterations in GCB DLBCL. Supplemental Figure 9. BCR internalization and My-T-BCR formation in glycosylation deficient cells. Supplemental Figure 10. NGI-1 synergizes with BTK and PI3K inhibitors.

  • Open Access

    Supplementary Figures S1-10 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas

    by Sebastian Scheich, Jiji Chen, Jiamin Liu, Frank Schnutgen, Julius C. Enssle, Michele Ceribelli, Craig J. Thomas, Jaewoo Choi, Vivian Morris, Tony Hsiao, et al.

    Supplemental Figure 1. IRF4-GFP knock-in reporter cell lines. Supplemental Figure 2. IRF4-GFP CRISPR screen in adult T-cell lymphoma and screen controls. Supplemental Figure 3. The OST is essential for DLBCL. Supplemental Figure 4. The role of the OST complex in radiation chimeras. Supplemental Figure 5. The B-cell receptor is glycosylated by the OST complex. Supplemental Figure 6. B-cell receptor deglycosylation leads to higher surface expression. Supplemental Figure 7. B-cell receptor deglycosylation leads to signaling changes in proximal BCR signaling components. Supplemental Figure 8. BCR deglycosylation leads to recruitment of CD22 on the cell surface to the BCR and signaling alterations in GCB DLBCL. Supplemental Figure 9. BCR internalization and My-T-BCR formation in glycosylation deficient cells. Supplemental Figure 10. NGI-1 synergizes with BTK and PI3K inhibitors.

  • Open Access

    Supplementary Figures S1-10 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas

    by Sebastian Scheich, Jiji Chen, Jiamin Liu, Frank Schnütgen, Julius C. Enssle, Michele Ceribelli, Craig J. Thomas, Jaewoo Choi, Vivian Morris, Tony Hsiao, et al.

    Supplemental Figure 1. IRF4-GFP knock-in reporter cell lines. Supplemental Figure 2. IRF4-GFP CRISPR screen in adult T-cell lymphoma and screen controls. Supplemental Figure 3. The OST is essential for DLBCL. Supplemental Figure 4. The role of the OST complex in radiation chimeras. Supplemental Figure 5. The B-cell receptor is glycosylated by the OST complex. Supplemental Figure 6. B-cell receptor deglycosylation leads to higher surface expression. Supplemental Figure 7. B-cell receptor deglycosylation leads to signaling changes in proximal BCR signaling components. Supplemental Figure 8. BCR deglycosylation leads to recruitment of CD22 on the cell surface to the BCR and signaling alterations in GCB DLBCL. Supplemental Figure 9. BCR internalization and My-T-BCR formation in glycosylation deficient cells. Supplemental Figure 10. NGI-1 synergizes with BTK and PI3K inhibitors.

  • Open Access

    Supplementary Tables S1-S12 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas

    by Sebastian Scheich, Jiji Chen, Jiamin Liu, Frank Schnütgen, Julius C. Enssle, Michele Ceribelli, Craig J. Thomas, Jaewoo Choi, Vivian Morris, Tony Hsiao, et al.

    Table S1. Brunello library sgRNA normalized read counts of IRF4 sorted CRISPR screens. Table S2. Segregation score of IRF4 sorted CRISPR screens. Table S3. Glycoproteomics in STT3A or STT3B KO cells. Table S4. Brunello sgRNA Library Normalized Read Counts of CRISPR screens. Table S5. CRISPR screen score of essentiality screens. Table S6. Glycoproteomics after NGI-1 treatment. Table S7.HBL1 and TMD8 Phosphotyrosone Phosphoproteome (pYome). Table S8. TMD8 CD79A-BioID. Table S9. HBL1 CD22 BioID. Table S10. Brunello library sgRNA normalized read counts of NGI-1 drug modified screen (TMD8). Table S11. CRISPR screen score of NGI-1 drug modifier screen. Table S12. TMD8 Drug screen Excess HSA.

  • Open Access

    Supplementary Figures S1-10 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas

    by Sebastian Scheich, Jiji Chen, Jiamin Liu, Frank Schnütgen, Julius C. Enssle, Michele Ceribelli, Craig J. Thomas, Jaewoo Choi, Vivian Morris, Tony Hsiao, et al.

    Supplemental Figure 1. IRF4-GFP knock-in reporter cell lines. Supplemental Figure 2. IRF4-GFP CRISPR screen in adult T-cell lymphoma and screen controls. Supplemental Figure 3. The OST is essential for DLBCL. Supplemental Figure 4. The role of the OST complex in radiation chimeras. Supplemental Figure 5. The B-cell receptor is glycosylated by the OST complex. Supplemental Figure 6. B-cell receptor deglycosylation leads to higher surface expression. Supplemental Figure 7. B-cell receptor deglycosylation leads to signaling changes in proximal BCR signaling components. Supplemental Figure 8. BCR deglycosylation leads to recruitment of CD22 on the cell surface to the BCR and signaling alterations in GCB DLBCL. Supplemental Figure 9. BCR internalization and My-T-BCR formation in glycosylation deficient cells. Supplemental Figure 10. NGI-1 synergizes with BTK and PI3K inhibitors.

  • Open Access

    Supplementary Tables S1-S12 from Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas

    by Sebastian Scheich, Jiji Chen, Jiamin Liu, Frank Schnütgen, Julius C. Enssle, Michele Ceribelli, Craig J. Thomas, Jaewoo Choi, Vivian Morris, Tony Hsiao, et al.

    Table S1. Brunello library sgRNA normalized read counts of IRF4 sorted CRISPR screens. Table S2. Segregation score of IRF4 sorted CRISPR screens. Table S3. Glycoproteomics in STT3A or STT3B KO cells. Table S4. Brunello sgRNA Library Normalized Read Counts of CRISPR screens. Table S5. CRISPR screen score of essentiality screens. Table S6. Glycoproteomics after NGI-1 treatment. Table S7.HBL1 and TMD8 Phosphotyrosone Phosphoproteome (pYome). Table S8. TMD8 CD79A-BioID. Table S9. HBL1 CD22 BioID. Table S10. Brunello library sgRNA normalized read counts of NGI-1 drug modified screen (TMD8). Table S11. CRISPR screen score of NGI-1 drug modifier screen. Table S12. TMD8 Drug screen Excess HSA.